Literature DB >> 1607246

Nitric oxide and endothelin-1 are important regulators of human ophthalmic artery.

I O Haefliger1, J Flammer, T F Lüscher.   

Abstract

The vascular endothelial cells have the ability to modulate local vascular tone by releasing relaxing factors such as nitric oxide or the vasoconstrictor peptide endothelin-1. Although this regulatory system is found in all vertebrates, there is a great heterogeneity in the release of these endothelium-derived substances, from one organ to an other, between large and small vessels, and between different species. Therefore, observations made in certain vascular beds or animals do not necessarily apply to human ophthalmic circulation. The present study was designed to investigate endothelial mediators in the human ophthalmic artery. The results show that in the human ophthalmic artery, nitric oxide is released under basal conditions and that its production can be markedly stimulated by bradykinin, acetylcholine, and particularly histamine, which cause profound vascular relaxation. In contrast, endothelin-1 evoked potent contractions, which were unaffected by the calcium antagonist nifedipine. However, upon re-exposure of the blood vessels to the peptide, marked tachyphylaxis occurred. These findings demonstrate that in the human ophthalmic artery, endothelium-derived nitric oxide and endothelin are very potent modulators of vascular tone, suggesting that they play an important role in the regulation of local blood flow in the eye. Hence, endothelium dysfunction may represent a new pathogenetic mechanism in disease states associated with altered blood flow to the eye, such as diabetes, hypertension, and some forms of low-tension glaucoma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1607246

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  47 in total

1.  Pituitary adenylate cyclase activating polypeptide and nitric oxide synthase are expressed in the rat ciliary ganglion.

Authors:  T Elsäs; R Uddman; H Mulder; F Sundler
Journal:  Br J Ophthalmol       Date:  1997-03       Impact factor: 4.638

2.  Effect of chronic inhibition of nitric oxide synthase on ocular blood flow and glucose metabolism in the rat.

Authors:  C O'Brien; P A Kelly; I M Ritchie
Journal:  Br J Ophthalmol       Date:  1997-01       Impact factor: 4.638

3.  Pharmacological evidence for the presence of functional beta(3)-adrenoceptors in rat retinal blood vessels.

Authors:  Asami Mori; Tomoyo Miwa; Kenji Sakamoto; Tsutomu Nakahara; Kunio Ishii
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-05-26       Impact factor: 3.000

4.  Effect of oxygen on relaxation of retinal pericytes by sodium nitroprusside.

Authors:  I O Haefliger; Q Chen; D R Anderson
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-06       Impact factor: 3.117

5.  Alterations of Ocular Hemodynamics Impair Ophthalmic Vascular and Neuroretinal Function.

Authors:  Shu-Huai Tsai; Wankun Xie; Min Zhao; Robert H Rosa; Travis W Hein; Lih Kuo
Journal:  Am J Pathol       Date:  2018-01-05       Impact factor: 4.307

Review 6.  Use of isolated ocular arteries in vitro to define the pathology of vascular changes in glaucoma.

Authors:  C H Buckley; P W Hadoke; C J O'Brien
Journal:  Br J Ophthalmol       Date:  1997-07       Impact factor: 4.638

7.  Vasoactive intestinal peptide- and nitric oxide synthase-containing nerve fibers in the rat ophthalmic artery have different origins.

Authors:  T Elsås; R Uddman; F Sundler
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-02       Impact factor: 3.117

8.  Plasma endothelin-1 concentrations in patients with retinal vein occlusions.

Authors:  A Iannaccone; C Letizia; S Pazzaglia; E M Vingolo; G Clemente; M R Pannarale
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

9.  Effects of NG-nitro-L-arginine methyl ester on the cardiovascular system of the anaesthetized rabbit and on the cardiovascular response to thyrotropin-releasing hormone.

Authors:  E E Seligsohn; A Bill
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

10.  Potential role for angiotensin-converting enzyme inhibitors in the treatment of glaucoma.

Authors:  Kazuyuki Hirooka; Fumio Shiraga
Journal:  Clin Ophthalmol       Date:  2007-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.